treatment

ALK receives positive recommendation for EURneffy 1 mg: A needle-free anaphylaxis treatment for children

Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’)…

1 month ago

Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural…

1 month ago

Real-World Commercial Experience with Ryoncil Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

January 26, 2026 18:45 ET  | Source: Mesoblast Limited NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

1 month ago

FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and…

1 month ago

Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD

SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration…

2 months ago

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys for the Treatment of ADHD

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration…

2 months ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope Treatment Center are encouraging individuals…

3 months ago

U.S. FDA Approves Agios AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name…

3 months ago

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

December 11, 2025 18:22 ET  | Source: Mesoblast Limited NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

3 months ago